

1 **1. Title**

2 Evaluation of the Point of Care Molecular Diagnostic Genedrive HCV ID Kit
3 for the detection of HCV RNA in clinical samples.
4

5 **Author names and affiliations.**

6

7 **Abhishek Padhi^a**

8 Department of Clinical Virology, ILBS, New Delhi, India. 110070^a

9 e-mail : abhio38450@gmail.com

10 **Ekta Gupta^a**

11 Department of Clinical Virology, ILBS, New Delhi, India. 110070^a

12 e-mail : ektagaurisha@gmail.com

13 **Gaurav Singh^a**

14 Department of Clinical Virology, ILBS, New Delhi, India. 110070^a

15 e-mail : gaurav_singh985@yahoo.com

16

17 **Reshu Agarwal^a**

18 Department of Clinical Virology, ILBS, New Delhi, India. 110070^a

19 e-mail : agarwalreshu286@gmail.com

20

21 **Manoj Kumar Sharma^b**

22 Department of Hepatology, ILBS, New Delhi, India. 110070^b

23 e-mail : manojkumardm@gmail.com

24

25 **Shiv Kumar Sarin^b**

26 Department of Hepatology, ILBS, New Delhi, India. 110070^b

27 e-mail : shivsarin@gmail.com

28

29 **Corresponding author**

30 Ekta Gupta^a

31 Department of Clinical Virology, ILBS, New Delhi, India. 110070^a

32 e-mail : ektagaurisha@gmail.com

33

34 **Highlights**

- 35 • Decentralisation of HCV RNA assays is the need of hour for finding
- 36 the missing millions.
- 37 • Genedrive HCV ID kit is one such assay which can qualitatively detect
- 38 HCV RNA and can be used as a point of care molecular assay thereby
- 39 reducing the dropouts and improving the HCV care cascade.

40 **2. Abstract**

41 **BACKGROUND**

42 Despite the availability of an effective treatment for HCV infection, major

43 bottle neck in the HCV care cascade is difficulty in getting the HCV RNA

44 done on serologically positive (antibody to HCV) patients. This is due to the

45 limited availability of HCV RNA test in the periphery. Nucleic acid

46 amplification testing at point of care might revolutionise the HCV care

47 continuum through its increased sensitivity, decreased turn around time

48 and ease of performance in the field. Genedrive is one such assay which has
49 recently got a CE- IVD certification.

50

51 **OBJECTIVES**

52 The diagnostic accuracy of Genedrive HCV ID kit for the qualitative
53 detection of HCV RNA was evaluated by comparing with Abbott HCV RNA
54 in an Indian demographic setting and across a range of different genotypes
55 commonly found in India.

56

57 **STUDY DESIGN**

58 For the assay evaluation 150 HCV RNA positive and 170 HCV RNA negative
59 samples as tested by Abbott HCV RNA assay (Abbott, Wiesbaden,
60 Germany) on Automated m200osp/m200ort platform, as per the
61 manufacturer's instructions, that were retrieved from -80°C in the Virology
62 repository were included in the study. All the samples were retrieved and
63 re tested for HCV RNA on Genedrive HCV ID kit and compared with Abbott
64 HCV RNA results.

65

66 **RESULTS**

67 Comparison of the Genedrive HCV ID kit with the Abbott Real Time HCV
68 assay revealed a sensitivity of 100 % (95% CI 97.9 to 100) and a specificity
69 of 100 % (95% CI 97.9 to 100) with a positive predictive value and negative

70 predictive value of 100%. Overall diagnostic accuracy of Genedrive was
71 found to be 100% (95% CI 98.9 to 100).

72

73 **CONCLUSION**

74 This study demonstrates that Genedrive HCV ID kit can be used for
75 decentralised testing of HCV and ultimately finding the missing million.

76

77 **Keywords**

78 Hepatitis C, Point of care test, HCV care cascade

79

80 **3. Background**

81 Hepatitis C virus (HCV) infection known for its chronicity resulted in
82 approximately 3,99 000 death in 2016 due to liver cirrhosis and
83 hepatocellular carcinoma [1]. Globally an estimated 71 million individuals
84 are infected with HCV out of which India is one of the six countries (others
85 being China, Pakistan, Nigeria, Egypt & Russia) where more than 50% of
86 the infected population resides[2] . A recent meta-analysis of HCV infection
87 in Indian population predicted around 3 – 9 million persons with active
88 Hepatitis C infection[3].

89

90 In 2016, the world health organization (WHO) launched its ambitious
91 strategy to eliminate viral hepatitis as a public threat by 2030 with a targets

92 of 90% reduction in incident cases of hepatitis B and C and a 65% reduction
93 in mortality[4]. In absence of vaccine against HCV and with the
94 introduction of directly acting antivirals (DAA) as an effective treatment
95 option, the onus squarely lies on an accurate diagnostic modality to achieve
96 this target.

97

98 The traditional approach to HCV diagnosis requires an HCV antibody test
99 followed by detection of HCV RNA to confirm viremia in HCV antibody
100 (HCV-ab) positive cases[1]. However, HCV-Ab detection includes
101 individuals who have cleared infection either spontaneously or through
102 treatment (estimating exposure as well as active infection), and also
103 includes false positives[5]. Furthermore low signal upon cut off presents a
104 diagnostic dilemma in the detection of HCV-ab[6]. Again the rapid
105 diagnostic tests pitted as the point of care test (POCT) have varied
106 sensitivity in different settings [7][8]. As a result, there has been a
107 paradigm shift towards using HCV PCR to determine accurately the
108 population prevalence of active infection[5].

109

110 While HCV RNA testing allows determining current status of infection thus
111 indicating individuals for treatment[9], it is confined to few high-end
112 laboratories. This centralized arrangement of HCV RNA testing may result
113 in patients losing to the follow up. Presently, the Cepheid Xpert HCV Viral
114 Load assay (Cepheid) is currently the only CE-IVD certified assay for

115 decentralized HCV VL determination. Though the Xpert HCV reported to
116 have a good performance, a high sample volume and need of electrical
117 power supply limits its field use[10]. Hence a robust, fully automated, high
118 throughput platform with a low turn around time is the need of the hour
119 that can serve as a single point molecular testing and refer to care centre so
120 that loss to follow up can be prevented particularly in the grass root level.

121

122 The Genedrive HCV ID Kit is one such platform which is European Union
123 CE approved, hand held battery operated fully automated platform
124 developed as a point-of-need molecular test for confirmation of chronic
125 HCV. The test is a cartridge based reverse transcriptase polymerase chain
126 reaction (RT-PCR) with an end point melt analysis of fluorescent molecular
127 probes. It has so far been validated in European and African settings with
128 the predominant HCV genotype as genotype 1,3,4 and 5 , and has
129 demonstrated good diagnostic accuracy (sensitivity 99.8 %, specificity
130 100%) [10]. The Genedrive HCV ID Kit requires validation in Indian
131 context where the circulation of HCV genotype is predominately 3 and 1 to
132 ensure suitability for the Indian population.

133

134

135

136

137

138

139 **4. Objectives**

140

141 The objectives of this study were to determine the diagnostic accuracy of
142 the Genedrive HCV ID Kit for HCV RNA detection, as a confirmatory test
143 for seropositive HCV patients in Indian demographic settings.

144

145 **5. Study Design**

146 **5.1. Samples**

147 Samples were retrieved from -80°C from the Virology data base, 150
148 positive and 170 as negative samples. All reference test data were collected
149 retrospectively, whilst Genedrive data were collected prospectively. All
150 specimens were remnants from routine testing of participants either
151 coming to the outpatient department or admitted in the hospital. The
152 specimens were plasma derived from blood collected in EDTA vacutainers
153 that had been stored at -80°C and were collected at ILBS between date
154 (October 2017) and date (Feb 2019).

155 Cases were determined as serologically positive for HCV with confirmation
156 of HCV RNA presence by the Abbott Real Time HCV assay (Reference Test,
157 henceforth called Abbot assay). Whilst the controls were determined as
158 serologically positive for HCV with confirmation of HCV RNA absence by
159 the Abbott assay (Reference Test).

160 HBV and HIV co-infected samples and samples with inadequate volume
161 were excluded from the analysis.

162 **5.2. Abbott Real Time HCV assay**

163 The Abbott assay was considered as reference test for detection of HCV
164 RNA in plasma samples. The test is quantitative with a 95% limit of
165 detection (LOD) of 12 IU/mL and measuring range of 12 to 10^8 IU/mL. 750
166 μ L of plasma per specimen was analysed using the Abbott assay on the
167 automated m200osp/m200ort platform, as per the manufacturer's
168 instructions.

169 **5.3. Genedrive HCV ID Kit**

170 In the Genedrive assay 30 μ L of plasma sample was added to the cartridge as
171 per the manufacturer's instructions. The Genedrive assay has a lower limit
172 of Detection of $3.37 \log_{10}$ IU/mL (2362 IU/mL) and kit has been validated
173 to work on all the genotypes(as per the kit literature). [11].

174

175 **5.4. HCV Genotyping**

176 Wherever a viral load of $>3 \log_{10}$ value was their the genotyping was done.
177 Genotyping of positive HCV RNA samples was performed as described
178 previously [12]. Briefly, genotyping of HCV RNA positive samples was
179 performed using the 5'UTR region of the viral RNA. A further confirmation
180 of genotype 1 samples was performed using the NS5B RNA region [13].
181 Genotyping of amplified and purified DNA was performed by bidirectional
182 sequencing using ABI Big Dye chemistry on the ABI 3500Dx series genetic

183 analyzer (Life Technologies, Waltham, MA). Sequence reads were aligned
184 using DNA Baser v3.5.1 (Heracle BioSoft SRL, Romania). A Basic Local
185 Alignment Search Tool (BLAST) was performed using obtained sequences
186 using the database of NCBI.

187

188

189

190 **5.5. Statistical analysis**

191 Statistical analysis was done using the Statistical SPSS software, version
192 22.0; Chicago, IL, USA). Continuous variables were expressed as mean \pm
193 SD or median (range) as appropriate and categorical variables were
194 expressed as percentage. All statistical tests were 2-tailed, and results were
195 statistically significant with a p value was less than 0.05.

196 **Ethics**

197 The study was approved by the Institutional ethics committee (IEC) of
198 Institute of Liver and Biliary Sciences (ILBS) and patient consent form
199 was waived off because of the use of left over clinical samples sent to
200 virology laboratory for routine diagnosis for HCV.

201

202 **6. Results**

203 **6.1. Sample details**

204 A total of 320 samples were included in the study, the baselines
205 characteristics of the study population is described. Of the 150 HCV
206 positive specimens, thirteen were below the Genedrive 95 % Limit of
207 Detection of $3.37 \log_{10}$ IU/mL (2362 IU/mL), whilst the remaining 137 were
208 above. Genotyping could be done in 105 samples.

209

210 *Table 1 – Baseline characteristics of the study population*

211

Variable	Number
Age (mean \pm SD) years	47.1 \pm 13.5
Male : female	1.8:1
Genotype (n=105)	
1	35 (33.3%)
3	68 (64.7%)
4	2 (1.9%)
Median RNA levels (\log_{10} IU/mL) (Range)	5.66 (2.01 – 7.47)

212

213

214 **6.2. Diagnostic accuracy**

215 Comparison of the Genedrive HCV ID Kit with the Abbott Real Time HCV
216 assay revealed a sensitivity of 100% (95% CI 97.6 to 100.0) and a specificity
217 of 100% (95 % CI 97.9 to 100), with a Positive Predictive Value and an

218 Negative Predictive Value of 100%. The overall diagnostic accuracy of the
219 Genedrive was determined at 100% (95% CI 98.9 to 100.0). Thirteen
220 specimens were included in the study below the stated Genedrive 95%
221 Limit of Detection of $3.37 \log_{10}$ IU/mL, these specimens had a median viral
222 load of $2.96 \log_{10}$ IU/mL and a range of $2.01 - 3.32 \log_{10}$ IU/mL. All
223 thirteen specimens were detected by Genedrive.
224 The lowest viral load that was detected by genedrive was 10^3 IU/ml (2.01
225 \log_{10} IU/ml).

226

227

228

229

230

231

232

233

234

235 *Table 2 – Comparison of HCV RNA detection between Abbott and*

236 *Genedrive assay.*

237

Abbott			
Undetecte	$<3.37 \log_{10}$	$>3.37 \log_{10}$	Total

		d	IU/mL	IU/mL	
	Undetectd	170	0	0	170
Genedrive	Detected	0	13	137	150
	Total	170	13	137	320

238

239

240

241 **6.3. Discrepant samples**

242 No discrepancy was observed between Genedrive with the Abbott HCV
243 assay.

244

245

246 **7. Discussion**

247 The present study aimed at evaluating the diagnostic accuracy of Genedrive
248 HCV assay for the qualitative detection of HCV RNA. A comparison of
249 Genedrive was done with Abbott Real Time HCV test, which offers viral
250 load and genotype testing and is currently considered as the gold standard.
251 Sensitivity of 100% (95% CI 97.6 to 100.0) and a specificity of 100% (95%
252 CI 97.9 to 100) was observed in our study. Studies done by Libre *et al* [10]
253 found high diagnostic sensitivity of 98.6% (95% CI 96.9% to 99.5%) and
254 100 % specificity (95% CI 99.3% to 100%) to detect HCV viraemia in
255 Western and South African laboratories.

256

257

258 WHO recommends that HCV serology testing be offered to individuals who
259 are part of a population with high HCV prevalence or who have a history of
260 HCV risk exposure/ behaviour and confirm the diagnosis of chronic HCV
261 infection by nucleic acid testing (NAT) for the detection of HCV RNA [9].
262 Currently HCV RNA testing is available in only few of a centralised medical
263 set ups resulting in < 1% of infected individual being aware of their
264 infection [14]. In Europe only 4.1% of individuals have been cured from
265 initial viraemia [15] and the situation is even more grim in resource limited
266 countries where it is <1 % [16][17]. In countries like Egypt and Mongolia the
267 prevalence of HCV is very high but the treatment rate is appalling, 0.12%
268 and 1.2% respectively, thereby suggesting that there is a negative
269 correlation between HCV prevalence and treatment [18][19]. Hence there is
270 an urgency in the need of a point of care molecular test which can be an
271 alternative to the conventional HCV NAATs, that can be used in the field
272 thereby decentralising the HCV diagnosis mainly in the resource limited
273 countries.

274

275 The Genedrive is a portable, fully integrated, PCR-based platform.
276 Genedrive has been designed to enable 'Direct to PCR' analysis of sample
277 matrices without the requirement to undertake pre-extraction of DNA, all
278 in approximately 90 minutes from sample collection. Genedrive is a 600
279 gram handheld thermocycler that qualitatively detects HCV RNA by NAAT

280 in plasma and serum samples. It fulfils the target product profile of HCV
281 diagnosis drafted by Foundation for innovative new diagnostics
282 (FIND)/WHO (specificity > 98% and sensitivity > 95%) and has shown
283 diagnostic accuracy for all 6 major genotypes. The limit of detection (LoD)
284 of Genedrive HCV RNA assay is 2362 IU/ml as compared to Abbott HCV
285 assay which is 12 IU/ml. But, recent WHO guidelines suggest that “a limit
286 of detection of 3000 IU/mL or lower would be acceptable and would
287 identify 95% of those with viraemic infection”[20]. The Genedrive HCV ID
288 Kit can potentially contribute to a decentralisation of clinical management
289 of chronic hepatitis C, which may result in expansion of the treatment
290 programme to rural areas of resource limited settings due it its relative ease
291 of use in comparison to current centralised laboratory based systems for
292 detection of HCV RNA.

293

294 Currently there are several NAAT point of care testings in pipeline and the
295 Cepheid Xpert HCV viral Load assay is currently the only CE- IVD certified
296 assay for decentralised HCV viral load determination. Despite having good
297 performance Xpert HCV test presents important limitations. The Xpert
298 HCV assay requires large volume of sample (1 ml), a constant power supply,
299 for which a basic laboratory set up is required. Moreover, the cartridge of
300 Xpert HCV assay requires guanidium thiocyanate as lysis reagent which is
301 highly toxic and requires special care while handling and disposal [12] [21] .

302 In contrast Genedrive is a battery operated handheld machine requiring
303 minimal amount of sample (30µl) and there is no toxic chemicals which
304 makes Genedrive ideal to be used in field settings.

305 The present study was carried out in a tertiary care centre and the test assay
306 was performed by highly trained technicians in a controlled environment.
307 Furthermore performance of Genedrive HCV assay requires a prospective
308 validation in a real life decentralised peripheral resource limited setting in
309 low- and middle income countries.

310 Finally, an important factor when assessing the feasibility of Point of
311 care technologies is their cost, both for platform and assays. However,
312 direct comparisons of costs to other platforms are challenging as there
313 are geographic differences and unknowns like subsidised or negotiated
314 pricing, distributor margins and duty . Furthermore, additional
315 costs associated with the platform should be considered, including
316 installation, maintenance, training and lifespan of the equipment and
317 tests. While the ultimate Genedrive costs remain to be defined, the
318 instrument is approximately \$5000, which is considerably less
319 than other molecular systems, and every Genedrive HCV test are going
320 to be available for \$30–\$40, counting on the country or region in
321 question.

322

323

324 **8. Conclusions**

325 Despite the lack of quantification of HCV viral load Genedrive HCV assay
326 offers a great potential to be used as a point of care NAAT thereby enabling
327 real time diagnosis, minimising loss to follow up and prompt management
328 of patients with chronic HCV infection in any clinical setting.

329 **CRedit authorship contribution statement**

330 **Abhishek Padhi** : Writing - original draft, Writing - review & editing,
331 Methodology. **Ekta Gupta** - Conceptualization, Formal analysis,
332 Investigation, Data curation, Writing - original draft, Writing - review &
333 editing, Supervision, Project administration. **Gaurav Singh** : Resources,
334 Methodology. **Reshu Agarwal** : Data curation. **M Sharma** : Writing -
335 review & editing, Supervision. **Shiv Kumar Sarin** : Project
336 administration, Supervision, Writing - review & editing.

337

338

339

340

341 **Competing Interest**

342 None declared

343

344 Funding

345 None

346

347 Acknowledgement

348 We thank Genedrive plc for supply of the instrument and Genedrive® HCV

349 ID Kit.

350

351

352 9. References

353

354

355 [1] Hepatitis C, (n.d.). [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/hepatitis-c)

356 [sheets/detail/hepatitis-c](https://www.who.int/news-room/fact-sheets/detail/hepatitis-c) (accessed February 14, 2020).

357 [2] Polaris Observatory HCV Collaborators, Global prevalence and genotype

358 distribution of hepatitis C virus infection in 2015: a modelling study,

359 *Lancet Gastroenterol Hepatol.* 2 (2017) 161–176.

360 [https://doi.org/10.1016/S2468-1253\(16\)30181-9](https://doi.org/10.1016/S2468-1253(16)30181-9).

361 [3] A. Goel, N. Seguy, R. Aggarwal, Burden of hepatitis C virus infection in

362 India: A systematic review and meta-analysis, *J. Gastroenterol. Hepatol.*

363 34 (2019) 321–329. <https://doi.org/10.1111/jgh.14466>.

- 364 [4] WHO-HIV-2016.06-eng.pdf [Internet]. [cited 2020 Feb 12]. Available
365 from:
366 [https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-](https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf)
367 [2016.06-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf) - Google Search, (n.d.).
368 [https://www.google.com/search?q=WHO-HIV-2016.06-](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
369 [eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+f](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
370 [rom%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhan](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
371 [dle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
372 [HIV-2016.06-](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
373 [eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+f](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
374 [rom%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhan](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
375 [dle%2F10665%2F246177%2FWHO-HIV-2016.06-](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
376 [eng.pdf&aqs=chrome..69i57.1603j0j7&sourceid=chrome&ie=UTF-8](https://www.google.com/search?q=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&oq=WHO-HIV-2016.06-eng.pdf+%5BInternet%5D.+%5Bcited+2020+Feb+12%5D.+Available+from%3A+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F246177%2FWHO-HIV-2016.06-eng.pdf&aqs=chrome..69i57j68j70j71j72j73j74j75j76j77j78j79j80j81j82j83j84j85j86j87j88j89j90j91j92j93j94j95j96j97j98j99&sourceid=chrome&ie=UTF-8)
377 (accessed February 14, 2020).
- 378 [5] E. Adland, G. Jesuthasan, L. Downs, V. Wharton, G. Wilde, A.L.
379 McNaughton, J. Collier, E. Barnes, P. Klenerman, M. Andersson, K.
380 Jeffery, P.C. Matthews, Hepatitis virus (HCV) diagnosis and access to
381 treatment in a UK cohort, *BMC Infectious Diseases*. 18 (2018) 461.
382 <https://doi.org/10.1186/s12879-018-3367-3>.
- 383 [6] N. Ballani, E. Gupta, Low signal-to-cutoff ratio (S/Co) in the diagnosis
384 of hepatitis C: A diagnostic dilemma?, *Indian J Gastroenterol*. 34 (2015)
385 413–414. <https://doi.org/10.1007/s12664-015-0593-0>.

- 386 [7] A. Mane, J. Sacks, S. Sharma, H. Singh, A. Tejada-Strop, S. Kamili, K.
387 Kacholia, R. Gautam, M. Thakar, R.S. Gupta, R. Gangakhedkar,
388 Evaluation of five rapid diagnostic tests for detection of antibodies to
389 hepatitis C virus (HCV): A step towards scale-up of HCV screening
390 efforts in India, PLoS ONE. 14 (2019) e0210556.
391 <https://doi.org/10.1371/journal.pone.0210556>.
- 392 [8] S. Chevaliez, J.-M. Pawlotsky, New virological tools for screening,
393 diagnosis and monitoring of hepatitis B and C in resource-limited
394 settings, J. Hepatol. 69 (2018) 916–926.
395 <https://doi.org/10.1016/j.jhep.2018.05.017>.
- 396 [9] WHO | Guidelines for the screening, care and treatment of persons with
397 hepatitis C infection, WHO. (n.d.).
398 <http://www.who.int/hepatitis/publications/hepatitis-c-guidelines/en/>
399 (accessed October 18, 2019).
- 400 [10] A. Llibre, Y. Shimakawa, E. Mottez, S. Ainsworth, T.-P. Buivan, R.
401 Firth, E. Harrison, A.R. Rosenberg, J.-F. Meritet, A. Fontanet, P. Castan,
402 A. Madejón, M. Laverick, A. Glass, R. Viana, S. Pol, C.P. McClure, W.L.
403 Irving, G. Miele, M.L. Albert, D. Duffy, Development and clinical
404 validation of the Genedrive point-of-care test for qualitative detection of
405 hepatitis C virus, Gut. 67 (2018) 2017–2024.
406 <https://doi.org/10.1136/gutjnl-2017-315783>.

- 407 [11] HCV-TPP-Report_17July2015_final.pdf, (n.d.).
408 [https://www.finddx.org/wp-content/uploads/2016/01/HCV-TPP-](https://www.finddx.org/wp-content/uploads/2016/01/HCV-TPP-Report_17July2015_final.pdf)
409 [Report_17July2015_final.pdf](https://www.finddx.org/wp-content/uploads/2016/01/HCV-TPP-Report_17July2015_final.pdf) (accessed October 18, 2019).
- 410 [12] E. Gupta, P. Agarwala, G. Kumar, R. Maiwall, S.K. Sarin, Point -of -
411 care testing (POCT) in molecular diagnostics: Performance evaluation of
412 GeneXpert HCV RNA test in diagnosing and monitoring of HCV
413 infection, *J. Clin. Virol.* 88 (2017) 46–51.
414 <https://doi.org/10.1016/j.jcv.2017.01.006>.
- 415 [13] D.G. Murphy, B. Willems, M. Deschênes, N. Hilzenrat, R. Mousseau,
416 S. Sabbah, Use of sequence analysis of the NS5B region for routine
417 genotyping of hepatitis C virus with reference to C/E1 and 5'
418 untranslated region sequences, *J. Clin. Microbiol.* 45 (2007) 1102–1112.
419 <https://doi.org/10.1128/JCM.02366-06>.
- 420 [14] HepatitisC_Strategy_WEB.pdf, (n.d.). [https://www.finddx.org/wp-](https://www.finddx.org/wp-content/uploads/2016/02/HepatitisC_Strategy_WEB.pdf)
421 [content/uploads/2016/02/HepatitisC_Strategy_WEB.pdf](https://www.finddx.org/wp-content/uploads/2016/02/HepatitisC_Strategy_WEB.pdf) (accessed
422 October 28, 2019).
- 423 [15] H. Razavi, S. Robbins, S. Zeuzem, F. Negro, M. Buti, A.-S. Duberg, F.
424 Roudot-Thoraval, A. Craxi, M. Manns, R.T. Marinho, B. Hunyady, M.
425 Colombo, S. Aleman, K. Antonov, P. Arkkila, K. Athanasakis, S. Blach,
426 M. Blachier, A.J. Blasco, F. Calinas, J.L. Calleja, P.B. Christensen, M.E.
427 Cramp, E. Croes, R.J. de Knegt, V. de Ledinghen, J.-M. Delile, C. Estes,
428 K. Falconer, M. Färkkilä, R. Flisiak, S. Frankova, I. Gamkrelidze, J.
429 García-Samaniego, J. Genov, J. Gerstoft, L. Gheorghe, A. Goldis, I.

430 Gountas, S. Gregorčič, M. Gschwantler, J. Gunter, W. Halota, L.
431 Harcouet, C. Hézode, P. Hoffmann, G. Horvath, I. Hrstic, P. Jarčuška,
432 D. Jelev, A. Jeruma, M. Kåberg, J. Kieran, L.A. Kondili, I. Kotzev, H.
433 Krarup, P. Kristian, M. Lagging, W. Laleman, P. Lázaro, V. Liakina, B.
434 Lukšić, M. Maimets, M. Makara, L. Mateva, M. Maticic, F.S. Mennini, R.
435 Mitova, C. Moreno, J. Mossong, K. Murphy, H. Nde, V. Nemecek, D.
436 Nonkovic, S. Norris, M. Oltman, A.L.H. Øvrehus, G. Papatheodoridis, K.
437 Pasini, D. Razavi-Shearer, K. Razavi-Shearer, H.W. Reesink, T. Reic, B.
438 Rozentale, S.D. Ryder, R. Salupere, R. Sarmento-Castro, C. Sarrazin,
439 J.D. Schmelzer, I. Schréter, C. Seguin-Devaux, K. Simojoki, M.
440 Simonova, P.J. Smit, K. Souliotis, D. Speiciene, J. Sperl, P. Stärkel, D.
441 Struck, V. Sypsa, L. Thornton, I. Tolmane, K. Tomasiewicz, J.
442 Valantinas, P. Van Damme, D. van de Vijver, A.J. van der Meer, D. van
443 Santen, H. Van Vlierberghe, D. Vandijck, S. Vella, J. Videčnik-Zorman,
444 W. Vogel, N. Weis, A. Hatzakis, Hepatitis C virus prevalence and level of
445 intervention required to achieve the WHO targets for elimination in the
446 European Union by 2030: a modelling study, *The Lancet*
447 *Gastroenterology & Hepatology*. 2 (2017) 325–336.
448 [https://doi.org/10.1016/S2468-1253\(17\)30045-6](https://doi.org/10.1016/S2468-1253(17)30045-6).
449 [16] A. Hatzakis, V. Chulanov, A.C. Gadano, C. Bergin, Z. Ben-Ari, J.
450 Mossong, I. Schréter, O. Baatarkhuu, S. Acharya, I. Aho, A.C. Anand,
451 M.I. Andersson, V. Arendt, P. Arkkila, K. Barclay, F. Bessone, S. Blach,
452 N. Blokhina, C.R. Brunton, G. Choudhuri, L. Cisneros, E.A. Croes, Y.A.

453 Dahgwahdorj, O. Dalgard, J.R. Daruich, N.R. Dashdorj, D. Davaadorj,
454 R.J. de Knecht, M. de Vree, C. Estes, R. Flisiak, E. Gane, E. Gower, W.
455 Halota, C. Henderson, P. Hoffmann, J. Hornell, D. Houlihan, S.
456 Hrusovsky, P. Jarčuška, D. Kershenobich, K. Kostrzewska, P. Kristian,
457 M. Leshno, Y. Lurie, A. Mahomed, N. Mamonova, N. Mendez-Sanchez,
458 S. Norris, E. Nurmukhametova, P. Nymadawa, M. Oltman, J. Oyunbileg,
459 T. Oyunsuren, G. Papatheodoridis, N. Pimenov, N. Prabdi-Sing, M.
460 Prins, S. Radke, A. Rakhmanova, K. Razavi-Shearer, H.W. Reesink, E.
461 Ridruejo, R. Safadi, O. Sagalova, J.F. Sanchez Avila, R. Sanduijav, V.
462 Saraswat, C. Seguin-Devaux, S.R. Shah, I. Shestakova, A. Shevaldin, O.
463 Shibolet, M.O. Silva, S. Sokolov, M. Sonderup, K. Souliotis, C.W.
464 Spearman, T. Staub, C. Stedman, E.A. Strebkova, D. Struck, V. Sypsa, K.
465 Tomasiewicz, L. Undram, A.J. van der Meer, D. van Santen, I.
466 Veldhuijzen, F.G. Villamil, S. Willemse, E. Zuckerman, F.R. Zuure, P.
467 Puri, H. Razavi, The present and future disease burden of hepatitis C
468 virus (HCV) infections with today's treatment paradigm - volume 2, J.
469 Viral Hepat. 22 Suppl 1 (2015) 26–45.
470 <https://doi.org/10.1111/jvh.12351>.

471 [17] H. Razavi, I. Waked, C. Sarrazin, R.P. Myers, R. Idilman, F. Calinas,
472 W. Vogel, M.C. Mendes Correa, C. Hézode, P. Lázaro, U. Akarca, S.
473 Aleman, I. Balık, T. Berg, F. Bihl, M. Bilodeau, A.J. Blasco, C.E. Brandão
474 Mello, P. Bruggmann, M. Buti, J.L. Calleja, H. Cheinquer, P.B.
475 Christensen, M. Clausen, H.S.M. Coelho, M.E. Cramp, G.J. Dore, W.

476 Doss, A.S. Duberg, M.H. El-Sayed, G. Ergör, G. Esmat, K. Falconer, J.
477 Félix, M.L.G. Ferraz, P.R. Ferreira, S. Frankova, J. García-Samaniego, J.
478 Gerstoft, J.A. Giria, F.L. Gonçales, E. Gower, M. Gschwantler, M.
479 Guimarães Pessôa, S.J. Hindman, H. Hofer, P. Husa, M. Kåberg, K.D.E.
480 Kaita, A. Kautz, S. Kaymakoglu, M. Krajden, H. Krarup, W. Laleman, D.
481 Lavanchy, R.T. Marinho, P. Marotta, S. Mauss, C. Moreno, K. Murphy,
482 F. Negro, V. Nemecek, N. Örmeci, A.L.H. Øvrehus, J. Parkes, K. Pasini,
483 K.M. Peltekian, A. Ramji, N. Reis, S.K. Roberts, W.M. Rosenberg, F.
484 Roudot-Thoraval, S.D. Ryder, R. Sarmiento-Castro, D. Semela, M.
485 Sherman, G.E. Shiha, W. Sievert, J. Sperl, P. Stärkel, R.E. Stauber, A.J.
486 Thompson, P. Urbanek, P. Van Damme, I. van Thiel, H. Van
487 Vlierberghe, D. Vandijck, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry,
488 A. Zekry, M. Cornberg, B. Müllhaupt, C. Estes, The present and future
489 disease burden of hepatitis C virus (HCV) infection with today's
490 treatment paradigm, *J. Viral Hepat.* 21 Suppl 1 (2014) 34–59.
491 <https://doi.org/10.1111/jvh.12248>.

492 [18] G.J. Dore, J. Ward, M. Thursz, Hepatitis C disease burden and
493 strategies to manage the burden (Guest Editors Mark Thursz, Gregory
494 Dore and John Ward), *J. Viral Hepat.* 21 Suppl 1 (2014) 1–4.
495 <https://doi.org/10.1111/jvh.12253>.

496 [19] H. Wedemeyer, G.J. Dore, J.W. Ward, Estimates on HCV disease
497 burden worldwide - filling the gaps, *J. Viral Hepat.* 22 Suppl 1 (2015) 1–
498 5. <https://doi.org/10.1111/jvh.12371>.

- 499 [20] WHO | Guidelines on hepatitis B and C testing, WHO. (n.d.).
500 [http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-](http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/)
501 [testing/en/](http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/) (accessed October 29, 2019).
- 502 [21] M.P. McHugh, A.H.B. Wu, S. Chevaliez, J.M. Pawlotsky, M. Hallin,
503 K.E. Templeton, Multicenter Evaluation of the Cepheid Xpert Hepatitis
504 C Virus Viral Load Assay, *J. Clin. Microbiol.* 55 (2017) 1550–1556.
505 <https://doi.org/10.1128/JCM.02460-16>.
506